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MCBS data are used to analyze the pre-
dictability of drug expenditures by Medicare
beneficiaries. Predictors include demo-
graphic characteristics and measures of
health status, the majority derived using
CMS’ diagnosis cost group/hierarchical
condition category (DCG/HCC) risk-adjust-
ment methodology. In prospective models,
demographic variables explained 5 percent
of the variation in drug expenditures.
Adding health status measures raised this
figure between 10 and 24 percent of the
variation depending on  the model configu-
ration. Adding lagged drug expenditures
more than doubled predictive power to 55
percent. These results are discussed in the
context of forecasting, and risk adjustment
for the proposed new Medicare drug benefit.
INTRODUCTION
Background and Aims
There are two reasons why researchers
and policymakers should care about the
predictability of prescription drug spending
in the Medicare population. First, is the
need to incorporate prescription drug expen-
ditures into Medicare spending forecasts in
light of the new Medicare drug benefit. The
most challenging forecast will be the first
one, which must be made without access to
actual drug spending data. Instead, the ini-
tial predictions will be drawn from simulat-
ed scenarios, undoubtedly using data from
the MCBS, in much the same manner as
that the U.S. Congressional Budget Office
and CMS estimated the costs of previous
drug benefit proposals. Second, this topic is
also important because payments to private
plans for administering the benefit must
incorporate a reasonable assessment of
risk.
There are surprisingly few studies that
directly address the issue of predictability of
drug spending. This may be explained in
part by the facts that private insurers rarely
offer free standing drug benefits, and that
the public programs that offer these benefits
(primarily State pharmaceutical assistance
programs) have not sought to develop pri-
vate risk-based contracts. In general, phar-
macy benefits managers do not assume the
majority of risk in contracts with either pub-
lic or private insurers, and there has been a
shift away from capitation in this market
(Booz Allen Hamilton, 2003). Two studies in
the early 1990s (Stuart et al., 1991; Coulson
and Stuart, 1992) examined the persistence
of drug spending in Pennsylvania’s PACE.
The authors were able to explain between 2
and 4 percent of the individual variance in
spending with only limited demographic
characteristics available from PACE enroll-
ment files. However, prior year spending
explained nearly 70 percent of the total vari-
ance in current year expenditures. This find-
ing leads to the conclusion that drug spend-
ing is highly persistent. 
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More recently, an unpublished study,
(Hogan, 2000) used 1992-1997 MCBS data
to estimate the predictability of drug
spending using several risk adjusters
designed for medical and hospital services.
He found R2 measures of 0.15 for both
prospective and concurrent versions of the
disability payment system (designed for
Medicaid), 0.07 for the prospective princi-
pal inpatient diagnostic cost group (PIP-
DCG) model, and 0.21 for a prospective
model containing claims-based condition
indicators. As in the prior study by Coulson
and Stuart (1992), adding previous year
prescription spending significantly increased
the R2. 
This existing research suggests that
drug expenditures are predictable and per-
sistent relative to the expenditures cur-
rently covered by Medicare. As a compari-
son, the demographic and health status
measures in the prospective DCG/HCC
model (CMS’s current methodology for
predicting Medicare expenditures) explain
roughly 9 percent of the variation in
Medicare-covered physician, and hospital
expenditures for the Medicare population
(Ash, Ellis, and Pope, 2000). In the context
of Medicare risk adjustment, Newhouse,
Buntin, and Chapman (1997), remarked
that, “It appears that anyone observing the
past spending of a given person could
explain about 20-25 percent of the variance
in actual annual spending.” 
The research findings reported in this
article build on the aforementioned stud-
ies. This study examined the predictability
of drug expenditures  for the Medicare
population using the most recent year of
MCBS data (2000), and CMS’ current
methodology for predicting Medicare Parts
A and B expenditures (the DCG/HCC
methodology). It analyzed the Medicare
population as a whole then separately as
individuals with and without drug cover-
age. Separate models are appropriate
because forecasting or risk adjustment on
behalf of the Medicare Program ultimately
pertain to an insured population, albeit one
that may contain individuals who are cur-
rently uninsured, and one would expect
the marginal impact of drug coverage to
vary by condition. The model of greatest
interest was a prospective model that used
the claims-based condition indicators
derived from the DCG/HCC methodology
to control for health status; the authors
also estimated several other models to pro-
vide context for the main results. The
emphasis was on attaining a basic finding
regarding predictability; the authors did
not seek to refine HCCs, conduct a detailed
analysis of individual predictors, perform
specification tests, or assess multiple mea-
sures of fit. 
METHODS
Data Source
The analysis is based on 1999 and 2000
MCBS Cost and Use Files. Beginning in
fall 1991, the MCBS is a longitudinal panel
survey of  a representative national sample
of the Medicare population conducted
under the auspices of CMS. Over 12,000
Medicare beneficiaries, both aged  and dis-
abled, living in the community or in institu-
tions are sampled from Medicare enroll-
ment files, and surveyed three times a year
using computer-assisted personal inter-
viewing. MCBS interviewers collect exten-
sive information on individuals’ use and
expenditures for health  services including
source of payment, as well as information
on health insurance, health and functional
status, socioeconomic status, and demo-
graphic characteristics. The MCBS Files
link Medicare claims to survey-reported
events, and provide complete expenditure,
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and source of payment data on all health
care services, including those not covered
by Medicare, notably prescription drugs
and long-term care.
Prescription drug utilization data in the
MCBS are based on self-reports of each
prescription filled and refilled during the
year. To assure accurate recall, respon-
dents are asked to keep bill records, and
prescription containers to show interview-
ers during the yearly interviews. During
return visits, MCBS interviewers provide
print-outs of the last recorded prescription
use and ask respondents to correct entries,
state whether these prescriptions are still
being taken, and report new medications
added since the last interview. Despite
these precautions, there are concerns
about underreporting. A recent compari-
son of MCBS self-reported medication use,
and pharmacy claims found under report-
ing rates of 17.0 percent for annual pre-
scription drug expenditures, and 17.7 per-
cent for number of prescriptions filled
(Poisal, 2003/2004). The current study
drew on both the survey data (for drug
expenditures and individual characteris-
tics), and the inpatient, outpatient, and
physician claims (for claims-based mea-
sures of health status).
Study Sample
The sample consisted of beneficiaries
enrolled in FFS Medicare Parts A and B
throughout 1999 and 2000 since a full year
of Medicare A  and B claims is required to
accurately assign DCG/HCC scores. In
addition, to be in the sample, beneficiaries
were required to have completed  three
MCBS survey rounds in each year since
persons with missed interviews have
incomplete prescription records.1 Finally,
respondents in long-term care facilities
were excluded because the MCBS does
not provide drug expenditure data on insti-
tutionalized beneficiaries. Applying these
study inclusion/exclusion criteria resulted
in a sample of 4,978 beneficiaries (roughly
40 percent of the MCBS total). Individuals
were deemed to have drug coverage if they
stated they had drug coverage in response
to survey questions or if there was indica-
tion of third party payment in the drug
claims data.
Study Variables
The dependent variable in all models
was annual drug expenditures for the year
2000 (including expenditures for drugs
currently  covered by Medicare) measured
in terms of the AWP for each prescription
filled during the year. The study used AWP
rather than the imputed transaction prices
listed in the MCBS to create a standardized
measure of individual drug expenditures.
Using AWP preserved variation  due to dif-
ferences in beneficiary utilization patterns,
and characteristics of individual prescrip-
tions (brand or generic, strength, and days
supply). In contrast, transaction prices
vary by drug coverage status because of
differences in the discounts and rebates
negotiated by various payers. While AWP
is an inflated measure of drug prices, it is
preferable in this context because the
emphasis is on the variability of drug
expenditures and on relative, rather than
absolute, levels of drug expenditure.   In
addition, there is no alternative approach
to drug pricing that is widely accepted. The
authors applied AWP to the individual drug
events in the MCBS, and used the proce-
dures developed by MCBS staff to create a
person-level annual measure of drug
expenditure from the claims data. 
The independent variables of greatest
interest were the summary measure of
predicted Medicare expenditures and the
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1 MCBS staff does impute annual drug expenditures for these
individuals, but the authors needed claim-level data in order to
apply the average wholesale price (AWP) prices. 
indicators for individual medical condi-
tions, both produced by the DCG/HCC
methodology. This methodology, created
by Health Economics Research (now RTI
International) is the Medicare Program’s
current risk-adjustment methodology, and
the basis for the selected significant dis-
ease model that will be used to reimburse
the M+C plans starting in January 2004. In
this application, the DCG/HCC model cre-
ated indicators for the presence of 189
medical conditions based on diagnoses
recorded on a patient’s Medicare claims
(physician, outpatient, and inpatient). The
DCG/HCC model then applied previously
calibrated weights (based on regression
coefficients) to these conditions to create a
summary score of the patients’ expected
Medicare expenditure under Parts A and B
including expenditures for the drugs that
Medicare currently covers.2 In the current
study, the models with indicators for indi-
vidual conditions exclude conditions with
fewer than approximately 20 cases in the
sample; this exclusion eliminated 59 condi-
tions.3 The purpose of this exclusion was
to reduce the degree of over fitting, and
establish a more accurate estimate of
adjusted R2.4,5
To provide a point of comparison, the
project team also estimated models in
which self-reported measures of 14 com-
mon diseases were used in place of the
DCG/HCC indicators. These included
heart disease, cancer, arthritis, lung dis-
ease, mental illness, Alzheimer’s, diabetes,
hypertension, osteoporosis, stroke, benign
prostatic hypertrophy, paralysis, Parkinson’s,
and hip fracture. In the majority of models,
predictor variables were based on 1999
data. In the concurrent model, however,
the HCC condition indicators were derived
using diagnoses measured in 2000. 
DRUG EXPENDITURE MODELS 
The study used ordinary least squares
(OLS) regression models with unweighted
observations  in order to maximize the effi-
ciency of parameter estimates. Linear mod-
els were chosen because they are often the
basis of risk-adjustment methodologies.6
Adjusted R2 was the measure of pre-
dictability.
The basic model was:
DEit=α+β1Xi+β2Hi+εit
with: 
DE=annual drug spending measured
using  AWP prices 
X=basic demographic characteristics
(age, sex, basis of Medicare entitlement
[disabled, aged, and aged with prior enti-
tlement due to disability], metropolitan
status, indicators for 10 detailed census
regions). 
H=health status.
We estimated six variants of this model.
Model 1 omitted the health status mea-
sure, and provided a baseline for subse-
quent results. Model 2 measured health
status via the 14 indicators for  self-report-
ed conditions. Model 3 replaced the  self-
reported conditions with 130 indicators for
individual conditions derived from 1999
Medicare claims using the HCC methodol-
ogy. This was the model of greatest inter-
est because it was a prospective model
based on Medicare claims data; this is the
information that would be appropriate, and
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2 For a discussion on the logic, structure, and coefficients of
DCG/HCC models refer to Ash, Ellis, and Pope (2000). Note
that there are variants of these models that pertain to other pop-
ulations, and draw on other data sources. Zhao et al. (2001)
describes a DCG model that incorporates information from
pharmacy claims.
3 This number of cases in the sample is approximate because the
list of conditions was finalized using a slightly different sample. 
4 Of the conditions eliminated, 48 probably do not entail  much
drug utilization, e.g., mental retardation and blindness. The
remainder does involve significant drug utilization, e.g., AIDS
and tuberculosis. 
5 Over fitting occurs when, as a result of small numbers of obser-
vations in particular cells estimated coefficients to fit individual
observations resulting in inflated estimate of an equation. 
6 The authors also estimated log-linear models; results were con-
sistent with those described in this article.
available for forecasting and risk-adjust-
ment. In addition, Medicare’s existing risk
adjustment methodology is the natural
point of departure for work in this area.
The next model replaced the indicators for
individual conditions with “ybase,” the sin-
gle summary measure of predicted Medicare
expenditure. Model 4 essentially con-
strained the relative importance of individ-
ual conditions in predicting drug expendi-
ture to be the same as their relative impor-
tance in predicting the physician, and inpa-
tient expenditures currently covered by
Medicare. While this constraint is unlikely
to hold, the comparative performance of
Models 3 and 4 sheds light on the loss in
potential fit in the HCC/DCG risk adjuster
is applied to M+C or Medicare Advantage
plans that offer drug benefits. (Note that
these plans generally do not offer full drug
coverage so the measure is far from exact.) 
Models 5 and 6 shed some light on the
persistence of drug expenditures. Model 5
used  the concurrent, rather than prospec-
tive, condition indicators, i.e. it drew on the
2000 rather than  1999 diagnoses to predict
drug expenditures in 2000. Comparing
Models 3 and 5 gives a sense   of the rela-
tive importance of chronic conditions,
which persist from year to year, in driving
drug expenditure. Model 6 is a variant of
Model 3, which includes an additional regres-
sor, lagged drug expenditures. While
lagged drug expenditures may not be avail-
able for forecasting, and are typically not
appropriate for payment applications
(because they blunt incentives for cost con-
tainment), this model offers direct insight
into the persistence of drug expenditures
and, by extension, into the potential for
adverse selection on the part of pur-
chasers, and risk selection on the part of
insurers in the market for drug insurance.
Adverse selection is the tendency of those
who are particularly likely to have above
average covered expenses to also have an
above average tendency to purchase insur-
ance. Adverse selection can drive up pre-
miums and/or cause insurers to lose
money. Similarly, risk selection is the ten-
dency of insurers to design their products,
direct their marketing, and otherwise act
to attract individuals likely to have below
average covered expenditures into their
pool. 
RESULTS
Table 1 presents descriptive characteris-
tics of the sample in 1999. More than one-
half the beneficiaries were female (56 per-
cent). About 17 percent were recipients of
Social Security disability insurance under
age 65. Another 6 percent were beneficia-
ries age 65 or over who had previously
been entitled to Medicare through Social
Security disability insurance. Just over one-
quarter of the sample was age 80 or over,
and about two-thirds of the beneficiaries
lived in urban areas. Relative to the popula-
tion with drug coverage, the population
without drug coverage was more likely to
be female, 80 years of age or over, and lives
in a rural area. The population without
drug coverage was less likely to be or have
been entitled to Medicare because of dis-
ability, perhaps because many of the dis-
abled currently have drug coverage through
the Medicaid Program. Similarly, the mean
predicted Medicare expenditure (a very
rough and somewhat problematic proxy
for the burden of illness) for those without
drug coverage ($4,769) was 79 percent of
the value for those with coverage ($6,054).7
Table 2 presents univariate statistics on
AWP-priced annual drug expenditures in
2000. The mean expenditure was $1,701
with a standard deviation of $2,091, reflect-
ing the presence of large positive outliers.
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7 Rates of the self-reported, and claims-based condition indica-
tors were included in our final report to CMS, and are available
on request from the authors.
Almost 8 percent of the sample reported no
drug expenditures8 and about one-fifth of
the sample had spending between $1 and
$500 for the year. At the other extreme, 16.4
percent had annual expenditures in excess
of $3,000. Table 2 also shows dramatic dis-
crepancies in standardized drug expendi-
tures between those with and without drug
coverage. Mean expenditures for those with-
out drug coverage ($1,013) were 52 percent
of the value for those with coverage ($1,949).
Sixteen percent of the sample without drug
coverage had no recorded drug expendi-
tures, while only 5 percent of the covered
sample lacked these expenditures. At the
other extreme, 20 percent of the covered
sample had expenditures in excess of $3,000
while 6 percent of those without drug cover-
age were in this range. These discrepancies
represent a combination of underlying dif-
ferences between the two populations, and
differences in drug utilization induced by
the presence of insurance.
Table 3 compares the adjusted R2 statis-
tics associated with the various models.9
Model 1  only used the age, sex, disability,
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Table 1
Demographic Characteristics and Health Status Measures: 1999
Beneficiaries With Beneficiaries With 
All Beneficiaries Drug Coverage No Drug Coverage
Characteristic N = 4,978 N = 3,659 N=1,319
Percent
Sex
Female 55.8 54.5 59.1
Male 44.2 45.5 40.9
Medicare Entitlement Status
Disabled 17.0 18.0 14.1
Aged1 5.6 6.2 3.9
Age
Under 65 Years 17.0 18.0 14.1
65-69 Years 17.2 17.7 15.7
70-74 Years 20.8 21.0 20.2
75-79 Years 18.2 18.1 18.6
80 Years or Over 26.8 25.1 31.5
Metropolitan Status
Rural 34.6 31.7 42.5
Urban 65.4 68.3 57.5
Detailed Census Regions
New England 2.9 2.9 2.8
Middle Atlantic 16.0 17.7 11.2
East North Central 17.3 17.2 17.6
West North Central 7.3 6.0 10.8
South Atlantic 22.2 21.7 23.7
East South Central 6.7 5.6 9.9
West South Central 11.1 11.3 10.6
Mountain 5.4 5.4 5.6
Pacific 9.6 10.7 6.6
Puerto Rico 1.5 1.5 1.3
Mean Predicted Medicare Expenditure2
HCC Methodology $5,713 $6,054 $4,769 
1 Previously disabled.
2 Predicted Medicare Parts A and B payment from the DCG/HCC model.
NOTES: Sample consisted of Medicare beneficiaries enrolled in FFS Medicare in both 1999 and 2000. Sample excluded beneficiaries in long-term
care facilities or with missing survey rounds in either year. DCG/HCC is diagnosis cost group/hierarchial condition category.
SOURCE: Centers for Medicare & Medicaid Services: Data from the Medicare Current Beneficiary Survey, 1999-2000.
8 In the community dwelling MCBS sample as a whole, this per-
centage was 9 percent.
9 Regression output for these models is available on request
from the authors.
and geographic variables. For the full sample,
this model yields an adjusted R2 of 0.05.
This indicates that demographic variables
explained little of the variation in the annu-
al drug expenditures of the Medicare ben-
eficiaries. Addition of the 14 indicators for
self-reported health conditions (Model 2)
doubled the adjusted R2 to 0.10. Model 3
replaced the self-reported health condi-
tions with the 130 indicators for health con-
ditions derived from the claims and yielded
an adjusted R2 of 0.23.  This result is very
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Table 2
Annual Per Capita Drug Expenditures1: 2000
All Beneficiaries With Beneficiaries With 
Beneficiaries Any Drug Coverage No Drug Coverage
Category N = 4,978 N=3,659 N=1,319
Statistics
Mean $1,701 (2,091) $1,949 (2,270) $1,013 (1,253)
Median 1,157 1,416 637 
Minimum 0 0 0 
Maximum 59,647 59,647 14,248 
Percent
Frequency Distribution
$0 7.9 5.0 16.2
>$0 to < $250 11.5 9.6 16.7
> $250 to < $500 8.8 7.8 11.8
> $500 to < $1,000 17.3 16.8 18.6
>$1,000 to < $2,000 23.8 25.0 20.6
>$2,000 to < $3,000 14.3 15.9 9.9
>$3,000 16.4 20.0 6.3
1 Drug expenditures measured using average wholesale price.
NOTES: Standard deviations are shown in parentheses. Sample consisted of Medicare beneficiaries enrolled in FFS. Medicare in both 1999 and
2000. Sample excluded beneficiaries in long-term care facilities or with missing survey rounds in either year.
SOURCE: Centers for Medicare & Medicaid Services: Data from the Medicare Current Beneficiary Survey, 1999-2000.
Table 3
Adjusted R2 Measures Associated with Models Predicting 2000 Drug Expenditures
Adjusted R2 (Level Models)
Beneficiaries Beneficiaries 
With Any Drug With No Drug 
All Beneficiaries Coverage Coverage
Model Description N =4,978 N =3,659 N =1,319
1 Prospective Model, Basic Demographic
Characteristics1 0.05 0.06 0.02
2 Prospective Model, Basic Demographic 
Characteristics Plus Self-Reported Health Conditions2 0.10 0.10 0.14
3 Prospective Model, Basic Demographic 
Characteristics Plus Claims Based Health Conditions3 0.23 0.22 0.26
4 Prospective Model, Basic Demographic 
Characteristics Plus Predicted Medicare Expenditure4 0.13 0.13 0.08
5 Concurrent Model3 0.24 0.23 0.27
6 Prospective Model 3 Plus Lagged Drug Expenditures 0.55 0.52 0.66
1 Basic demographic characteristics: age (4 categories), currently disabled, previously disabled, sex, status, metropolitan status, and detailed census
regions (10).
2 Self-reported conditions from the MCBS: heart disease, cancer, arthritis, lung disease, mental illness, Alzheimer’s, diabetes, hypertension, 
osteoporosis, stroke, benign prostatic hypertrophy, paralysis, Parkinson’s, and hip fracture.
3 Claims-based health conditions as defined and calculated by the DCG/HCC model (130 conditions). Conditions with less than approximately 20
cases were excluded.
4 Predicted Medicare Parts A and B payment from DCG/HCC model.
NOTES: DCG/HCC is diagnosis cost group/hierarchical condition category. Unadjusted R 2 for models 1-6 (all beneficiaries) were 0.05, 0.11, 0.25,
0.13, 0.26, and 0.56, respectively. Sample consisted of Medicare beneficiaries enrolled in FFS Medicare in both 1999 and 2000. Sample excluded
beneficiaries in long-term care facilities or with missing survey rounds in either year.
SOURCE: Centers for Medicare & Medicaid Services: Data from the Medicare Current Beneficiary Survey, 1999-2000.
close to Hogan’s (2000) R2 of 0.21 when
individual conditions were used to prospec-
tively predict 1992-1997 drug expenditures
in the MCBS.10
In Model 3, 12 conditions were statisti-
cally significant, and associated with more
than $500 in prescription drug spending.
They were diabetes with ophthalmologic
manifestations ($627, standard error [s.e.]
$234), inflammatory bowel disease ($1,217,
s.e. $327), rheumatoid arthritis and inflam-
matory conditions ($503, s.e. $129), schiz-
ophrenia ($1,980, s.e. $206), major depres-
sive bipolar, and paranoid ($1,246, s.e. $155),
depression ($512, s.e. $145), Parkinson’s
and Huntington’s diseases ($651, s.e.
$260), congestive heart failure ($556, s.e.
$106), unstable angina, and other acute
ischemic conditions ($565, s.e. $165),
chronic obstructive pulmonary disease
($509, s.e. $88), fibrosis of lung and other
chronic lung disorders ($546, s.e. $220),
and kidney transplant status ($4,292, s.e.
$435).11 These are all chronic conditions.
Model 4 collapsed these indicators to a
single measure of expected Medicare
expenditure, resulting in an adjusted R2 of
0.13. This figure was slightly higher than
the adjusted R2 associated with the self-
reported conditions in this study, roughly
comparable to Hogan’s (2000) result for
the disability payment system (DPS)
adjuster, and higher than his result with
the PIP-DCG). A $100 increase in predict-
ed Medicare expenditure (based on diag-
noses recorded the year before) was asso-
ciated with a $12 increase in drug expendi-
tures. The associated s.e. was $0.71. Model
5, the concurrent variant of Model 3, gen-
erated an adjusted R2 of 0.24, which is only
1 percentage point higher than Model 3.
Consistent with prior research, this study
found that drug expenditures were highly
persistent. Model 6, which added lagged
drug expenditures to Model 3, led to an
adjusted R2 of 0.55. A $100 increase in prior
year’s expenditures was associated with an
$82 increase in current year’s expenditure
(s.e. $1.38). In this model, the demograph-
ic characteristics and health status mea-
sures generally lost significance.
Models estimated separately for benefi-
ciaries with and without any drug coverage
offered preliminary evidence that drug
expenditures are less predictable for popu-
lations with drug coverage than for popula-
tions without drug coverage. For the popu-
lation with drug coverage, Model 3 yielded
an adjusted R2 of 0.22; for the population
without coverage, the adjusted R2 was 0.26.
This 4 percentage-point discrepancy essen-
tially persisted in the other models with
condition indicators, and became more
pronounced when lagged drug expendi-
tures were added as an additional regres-
sor. (The gap also widened in models [not
shown] in which the dependent variable
was entered in logarithmic form.) The
exceptions to this pattern were Model 1
(demographic variables only, of less inter-
est), and Model 4 (health status measured
as the single summary measure of predict-
ed Medicare expenditure), in which adjust-
ed R2 for the covered population was 0.13,
and for the uncovered population was 0.08.
Further work is needed to determine
whether this gap is indeed a true differ-
ence in predictability or an artifact of over
fitting, the uncovered sample also being
the smaller sample. 
DISCUSSION AND CONCLUSIONS
The central result of this study is that it
was possible to predict approximately 23
percent of the variation in Medicare drug
expenditures using a prospective model
that included basic demographic charac-
teristics and health status measures. These
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10 Hogan’s models included age, sex, and indicators for year and
drug coverage as additional controls.
11 Excluding the ESRD population did not affect the central
results of this study.
health status measures were indicators for
medical conditions, derived from Medicare
claims using Medicare’s current risk-
adjustment methodology.  This figure is
high relative to the predictability of the
expenditures currently covered by Medicare.
The majority of the model’s explanatory
power stemmed from the health status
measures. The basic demographic vari-
ables alone explained only 5 percent of the
variation in prescription drug expendi-
tures. The claims-based indicators also sig-
nificantly out-performed indicators for 14
self-reported health conditions and, not
surprisingly, the single summary measure
of expected Medicare expenditure. This
latter result indicates that the relative pre-
dictive power of the individual conditions
differed between drug expenditures and
Medicare Parts A and B spending. In other
words, the conditions that predicted high
Medicare expenditures were not necessar-
ily the conditions that predicted high drug
expenditures and vice versa. Interestingly,
the performance of the prospective model
was virtually equivalent to the perfor-
mance of the concurrent model, suggest-
ing that it was persistent, chronic condi-
tions that drove drug expenditures. 
This study also confirmed prior work by
finding that drug expenditures were highly
persistent. This persistence, combined
with the variation in expenditures among
individuals, suggests the potential for pow-
erful adverse selection if individuals are
free to decide whether or not to purchase
drug insurance at a single market price.
Also, the fact that lagged drug expendi-
tures added significant explanatory power
to the expenditure equation even when
condition indicators are present means
that insurers in competitive markets will
retain strong incentives for risk selection
even if their rates are case-mix adjusted.
The study also contains preliminary evi-
dence that drug expenditures may be
more predictable for populations without
drug coverage. While this finding requires
confirmation, it is consistent with the
notion that drug coverage induces addi-
tional, discretionary drug spending.
This research had several important lim-
itations. First, the sample exclusion crite-
ria, while necessary to ensure complete
and accurate data, mean that the sample
was not representative of the Medicare
population as a whole, and hence, results
cannot be generalized. Second, this study
used 2000 data and does not reflect new
innovations in drug therapy or in the man-
agement of drug benefits. Third, the ideal
approach to standardized pricing would be
to use a weighted average of the prices
paid by beneficiaries and their insurers,
not the AWP; unfortunately, there is not a
source of such data in common use.
Finally, predictability estimates may be
slightly inflated due to over fitting especial-
ly for the subsample without drug cover-
age, and for models containing claims-
based condition indicators.
Further work on this general topic
might seek to refine the condition indica-
tors for the specific purpose of forecasting
drug expenditures, and might examine
alternative approaches to modeling health
care expenditures, such as those proposed
by Veazie, Manning, and Kane (2003). Fit
could be evaluated using a wider range of
metrics and split sample techniques. One
might also seek more recent data sources
with large sample sizes, potentially drug
claims that could be linked to Medicare
data. In addition, policy-oriented work with
a focus on Medicare drug benefits might
replace total expenditures with a variable
that incorporated the cost sharing, drug
pricing, and utilization management fea-
tures of  the specific option or options
under study. Finally, additional research
should seek to confirm or  refute the find-
ing that drug expenditures are less predi-
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cable for insured populations, examine
which patients and which types of drugs
are most sensitive to insurance, and con-
sider (to the extent possible) the social and
clinical value of any expected utilization
effects. This information would be useful
both to policy design, and to forecasting
the impacts of a given policy. 
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